NASDAQ$SLDB
Solid Biosciences Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Solid Biosciences reported Q2 2021 financial results and provided a business update.
Solid Biosciences reported collaboration revenue of $3.6 million for the second quarter of 2021, driven by their collaboration agreement with Ultragenyx. The company's research and development expenses increased to $15.5 million, and they ended the quarter with approximately $249 million in cash and investments.
- Advanced clinical activities to prepare for the next patient to be dosed in the IGNITE DMD clinical trial of SGT-001, with next patient dosing anticipated in Q4 2021.
- Progressed the next generation Duchenne gene therapy program, SGT-003.
- Advanced the Duchenne collaboration with Ultragenyx.
- Ended Q2 with approximately $249 million in cash and investments, providing a cash runway into Q4 2022.
Headline financials
Revenue & EPS history
Solid Biosciences · Revenue · Quarterly
$3.59M
Forward guidance
The company expects that its cash, cash equivalents and available-for-sale securities will enable Solid to invest in its Duchenne gene therapy programs and capital expenditures into the fourth quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-3.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+3.1%
Avg return
30 days after
50%
16 / 32 earnings
Positive
+19.0%
Q2 2019
Best reaction
-72.2%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.0% | +14.2% | +14.7% | |
| Q3 2025 | +7.4% | +15.3% | +46.8% | |
| Q1 2025 | +8.3% | +14.2% | +71.2% | |
| Q4 2024 | +5.3% | -9.6% | -50.5% | |
| Q3 2024 | -2.9% | +0.8% | -15.0% | |
| Q2 2024 | +16.6% | +23.9% | +7.8% | |
| Q1 2024 | -6.6% | -8.4% | -20.7% | |
| Q4 2023 | +7.7% | +17.2% | -9.0% | |
| Q3 2023 | -23.9% | -22.9% | +80.7% | |
| Q2 2023 | -1.1% | -1.1% | -12.9% | |
| Q1 2023 | +1.9% | +1.0% | +2.3% | |
| Q4 2022 | -2.6% | +5.0% | +28.6% | |
| Q3 2022 | +3.9% | +4.6% | -0.8% | |
| Q2 2022 | +6.5% | +15.3% | -10.8% | |
| Q1 2022 | -24.2% | -29.0% | -23.9% | |
| Q4 2021 | -7.0% | +34.0% | -0.9% | |
| Q3 2021 | +13.9% | +3.7% | -21.8% | |
| Q2 2021 | -3.0% | -7.1% | -1.1% | |
| Q1 2021 | -20.0% | -15.8% | -7.4% | |
| Q4 2020 | -32.5% | -38.9% | -44.3% | |
| Q3 2020 | -0.6% | -1.9% | +12.0% | |
| Q2 2020 | +0.0% | +8.0% | -13.6% | |
| Q1 2020 | -12.2% | -7.3% | +2.1% | |
| Q4 2019 | +18.5% | -4.5% | -22.0% | |
| Q3 2019 | -72.2% | -68.1% | -61.3% | |
| Q2 2019 | +19.0% | +79.9% | +96.1% | |
| Q1 2019 | -31.2% | -34.2% | -43.2% | |
| Q4 2018 | +0.3% | +4.7% | -9.9% | |
| Q3 2018 | +13.8% | +3.8% | -2.6% | |
| Q2 2018 | -1.2% | -1.1% | +2.5% | |
| Q1 2018 | +11.6% | +15.2% | +19.6% | |
| Q4 2017 | +1.9% | +12.7% | +86.2% | |
| Q3 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro